• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer.赛托珠单抗戈维汀及其他靶向乳腺癌中滋养层细胞表面抗原2（Trop-2）的抗体药物偶联物
Ann Transl Med. 2022 Sep;10(18):1031. doi: 10.21037/atm-22-1892.
2
Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.戈沙妥珠单抗用于激素受体阳性和三阴性乳腺癌
Mol Cell Pharmacol. 2023;15(1):1-5.
3
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.高表达人滋养细胞表面标志物（Trop-2）的宫颈癌对抗体药物偶联物 sacituzumab govitecan 高度敏感。
Sci Rep. 2020 Jan 22;10(1):973. doi: 10.1038/s41598-020-58009-3.
4
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.靶向 TROP-2 并包含 SN-38 的抗体药物偶联物：抗 TROP-2 sacituzumab govitecan 的案例研究。
MAbs. 2019 Aug/Sep;11(6):987-995. doi: 10.1080/19420862.2019.1632115. Epub 2019 Jul 18.
5
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.注射用戈沙妥珠单抗：一种用于治疗难治性、转移性三阴性乳腺癌的抗体药物偶联物。
Ann Pharmacother. 2021 Jul;55(7):921-931. doi: 10.1177/1060028020966548. Epub 2020 Oct 17.
6
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.Sacituzumab govitecan：一种新型抗体药物偶联物的过去、现在和未来及未来展望。
Future Oncol. 2022 Sep;18(28):3199-3215. doi: 10.2217/fon-2022-0407. Epub 2022 Sep 7.
7
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.滋养层细胞表面抗原2（TROP-2）作为一种新型癌症靶点的出现。
Oncotarget. 2018 Jun 22;9(48):28989-29006. doi: 10.18632/oncotarget.25615.
8
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.注射用戈沙妥珠单抗治疗转移性三阴性乳腺癌的临床概述和潜在毒性的管理。
Oncologist. 2021 Oct;26(10):827-834. doi: 10.1002/onco.13878. Epub 2021 Jul 10.
9
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.在人输卵管浆液性癌中，针对滋养层细胞表面抗原 2（Trop-2）的抗体药物偶联物 sacituzumab govitecan 的体内外活性。
Gynecol Oncol. 2020 Feb;156(2):430-438. doi: 10.1016/j.ygyno.2019.11.018. Epub 2019 Dec 12.
10
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.戈沙妥珠单抗（Sacituzumab Govitecan）的临床前活性研究，这是一种靶向滋养层细胞表面抗原2（Trop-2）并与伊立替康活性代谢物（SN-38）偶联的抗体药物偶联物在卵巢癌中的研究。
Front Oncol. 2020 Feb 12;10:118. doi: 10.3389/fonc.2020.00118. eCollection 2020.

引用本文的文献

1
A meta-analysis and systematic review of the first Trop-2-targeting antibody-drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer.首个靶向Trop-2的抗体药物偶联物（戈沙妥珠单抗）治疗转移性乳腺癌的荟萃分析与系统评价
Eur J Clin Pharmacol. 2025 Jul 7. doi: 10.1007/s00228-025-03876-w.
2
Unexpected Long-Term Survival and Downstaging in Oligometastatic Non-Small Cell Lung Cancer Treated with Multimodal Therapy.多模式治疗的寡转移非小细胞肺癌患者的意外长期生存和降期
J Clin Med. 2025 May 13;14(10):3394. doi: 10.3390/jcm14103394.
3
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.靶向滋养层细胞表面抗原2的抗体药物偶联物达波妥单抗德鲁替康在子宫浆液性癌中的临床前活性
Cancer Res Commun. 2025 May 1;5(5):774-782. doi: 10.1158/2767-9764.CRC-25-0057.
4
Generation and Characterization of SORT1-Targeted Antibody-Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor.针对 SORT1 阳性乳腺癌的 SORT1 靶向抗体药物偶联物的构建与鉴定。
Int J Mol Sci. 2023 Dec 18;24(24):17631. doi: 10.3390/ijms242417631.
5
CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets.基于嵌合抗原受体的实体瘤免疫疗法——新兴靶点综述
Cancers (Basel). 2023 Feb 11;15(4):1171. doi: 10.3390/cancers15041171.

本文引用的文献

1
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.在晚期或转移性 HR+/HER2-和三阴性乳腺癌中应用德曲妥珠单抗偶联物：TROPION-PanTumor01 研究的 I 期结果。
J Clin Oncol. 2024 Jul 1;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 23.
2
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.戈沙妥珠单抗作为转移性三阴性乳腺癌二线治疗的3期ASCENT研究亚组分析
NPJ Breast Cancer. 2022 Jun 9;8(1):72. doi: 10.1038/s41523-022-00439-5.
3
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.曲妥珠单抗-德曲妥珠单抗用于既往治疗的 HER2 低表达晚期乳腺癌。
N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
4
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.曲妥珠单抗-德鲁替康与曲妥珠单抗-美坦新用于乳腺癌。
N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022.
5
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌无事件生存。
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
6
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.欧洲肿瘤内科学会转移性乳腺癌患者诊断、分期及治疗临床实践指南
Ann Oncol. 2021 Dec;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019. Epub 2021 Oct 19.
7
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.在转移性三阴性乳腺癌患者中 sacituzumab govitecan 与化疗对比的 III 期 ASCENT 研究中的生物标志物分析。
Ann Oncol. 2021 Sep;32(9):1148-1156. doi: 10.1016/j.annonc.2021.06.002. Epub 2021 Jun 8.
8
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.TROPHY-U-01 研究：在铂类化疗和检查点抑制剂治疗后进展的转移性尿路上皮癌患者中 sacituzumab govitecan 的 II 期开放标签研究。
J Clin Oncol. 2021 Aug 1;39(22):2474-2485. doi: 10.1200/JCO.20.03489. Epub 2021 Apr 30.
9
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.Sacituzumab Govitecan 治疗转移性三阴性乳腺癌。
N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485.
10
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.乳腺癌的新辅助化疗、内分泌治疗和靶向治疗：ASCO 指南。
J Clin Oncol. 2021 May 1;39(13):1485-1505. doi: 10.1200/JCO.20.03399. Epub 2021 Jan 28.

Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer.

作者信息

Matusz-Fisher Ashley, Tan Antoinette R

机构信息

Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

出版信息

Ann Transl Med. 2022 Sep;10(18):1031. doi: 10.21037/atm-22-1892.

DOI:10.21037/atm-22-1892
PMID:36267779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9577799/
Abstract
摘要